Egetis Therapeutics AB Stock
Stocks
EGTX
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq Stockholm
01:00:00 11/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 11.10 SEK | -0.18% |
|
+11.67% | +107.87% |
| 11-09 | Stockholm exchange rises slightly at open, Qliro surges on bid | FW |
| 11-09 | Stockholm bourse set to open slightly lower | FW |
| Market Cap | 5.16B 522M 468M 431M 391M 741M 48.9B 762M 2.06B 26.2B 1.96B 1.92B 82.82B | P/E 2026 * |
131x | P/E 2027 * | -42.9x |
|---|---|---|---|---|---|
| Enterprise Value | 4.23B 427M 383M 353M 321M 607M 40.07B 624M 1.68B 21.47B 1.6B 1.57B 67.86B | EV / Sales 2026 * |
37.4x | EV / Sales 2027 * | 8.67x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| EGTX | Delayed | |
London S.E.
| 0ABW | Delayed | |
|
CBOE
| Real-time | ||
|
OTC Markets
| PDPHF | Delayed | |
|
Boerse Muenchen
| P0F | Real-time | |
|
Börse Stuttgart
| P0F | Delayed | |
|
Deutsche Boerse AG
| P0F | Delayed | |
|
CBOE
| 0ABW | Real-time |
Last Transcript: Egetis Therapeutics AB
| 1 day | -0.18% | ||
| 1 week | +11.67% | ||
| Current month | +10.34% | ||
| 1 month | +11.78% | ||
| 3 months | +58.80% | ||
| 6 months | +71.30% | ||
| Current year | +107.87% |
| 1 week | 11.06 |  | 11.16 |
| 1 month | 8.96 | | 11.16 |
| Current year | 4.23 | | 11.16 |
| 1 year | 3.62 | | 11.16 |
| 3 years | 3.02 | | 11.16 |
| 5 years | 3 | | 11.16 |
| 10 years | 3 | | 22.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 16/06/2017 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 31/12/2017 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01/01/2017 | |
Mats Blom
CHM | Chairman | 61 | 06/05/2024 |
Behshad Sheldon
BRD | Director/Board Member | 63 | 01/01/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 2/9/26 | Sell | Executive/Senior Manager | -594 | 0.0001% | ||
| 31/8/26 | Exercice | Chief Financial Officer | 1,099 | 0.0002% | ||
| 31/8/26 | Buy | Chief Operating Officer | 1,099 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | +11.67% | +79.90% | +117.22% | 522M | |
| +0.01% | +11.10% | +60.83% | +70.43% | 68.32B | |
| +1.22% | +9.56% | +15.97% | +90.23% | 60.26B | |
| +0.24% | +1.35% | +23.78% | +97.55% | 55.86B | |
| +1.60% | +19.44% | +28.80% | +112.95% | 48.43B | |
| -1.32% | +4.78% | +29.15% | +40.40% | 45.34B | |
| -3.54% | -0.60% | +207.76% | +879.50% | 41.76B | |
| -3.33% | +6.90% | +22.78% | +48.07% | 34.5B | |
| -2.19% | -3.71% | +90.94% | +66.33% | 33.8B | |
| -1.77% | +0.83% | +46.57% | -0.16% | 25.96B | |
| Average | -0.93% | +6.40% | +60.65% | +152.25% | 41B | |
| Weighted average by Cap. | -0.67% | +5.57% | +55.33% | +153.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 113M 11.41M 10.24M 9.43M 8.57M 16.21M 1.07B 16.67M 45M 573M 42.83M 41.93M 1.81B | 512M 51.74M 46.4M 42.76M 38.83M 73.49M 4.85B 75.54M 204M 2.6B 194M 190M 8.22B |
| Net income | 414M 41.84M 37.52M 34.58M 31.4M 59.43M 3.92B 61.09M 165M 2.1B 157M 154M 6.64B | -42.62M -4.31M -3.86M -3.56M -3.23M -6.12M -404M -6.29M -16.98M -216M -16.16M -15.82M -684M |
| Net Debt | -932M -94.18M -84.46M -77.84M -70.69M -134M -8.83B -138M -371M -4.73B -353M -346M -14.96B | -720M -72.76M -65.25M -60.14M -54.62M -103M -6.82B -106M -287M -3.66B -273M -267M -11.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/11/26 | SEK 11.10 | -0.18% | 4,722,428 |
| 09/11/26 | SEK 11.12 | 0.00% | 4,571,816 |
| 06/11/26 | SEK 11.12 | 0.00% | 8,794,096 |
| 05/11/26 | SEK 11.12 | +11.31% | 33,332,869 |
| 04/11/26 | SEK 9.990 | +0.50% | 4,746,802 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EGTX Stock
Select your edition
All financial news and data tailored to specific country editions
